Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well

After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet